Reprint
Clostridioides difficile Infection, 2nd Edition
Edited by
July 2024
144 pages
- ISBN978-3-7258-1642-2 (Hardback)
- ISBN978-3-7258-1641-5 (PDF)
https://doi.org/10.3390/books978-3-7258-1641-5 (registering)
This book is a reprint of the Special Issue Clostridioides difficile Infection, 2nd Edition that was published in
Biology & Life Sciences
Medicine & Pharmacology
Summary
This reprint collects multidisciplinary research articles focused on Clostridioides difficile infection. The contributions collected here shed some light on grey areas of our knowledge of Clostridioides difficile, including the identification of Clostridioides difficile carriers at high risk of developing infection or infection recurrence, the intra-hospital and community spread of Clostridioides difficile, the rate of Clostridioides difficile infection during the SARS-CoV-2 pandemic, the current treatment approach, and the use of bezlotoxumab to prevent infection recurrence.
Format
- Hardback
License and Copyright
© 2024 by the authors; CC BY-NC-ND license
Keywords
Clostridioides difficile; enteritis; ileostomy; dehydration; Clostridioides difficile (C. difficile); faecal microbiota transplantation; FMT; FMT regulation; regulatory framework; EU Tissue and Cell Directive; neutralization assay; toxin immunoassay; receiver operating characteristic curve; Clostridioides difficile; metronidazole; biofilm; motility; morphology; adherence; colonization; Clostridioides difficile; chronic kidney disease; malnutrition; pseudomembranous enterocolitis; fidaxomicin; CDI; rCDI; Clostridioides difficile; randomized clinical trials; RCT; primary CDI; Clostridioides difficile; TcdB; toxin; bezlotoxumab; recurrence of CDI; CDI recurrence prevention; cost-effectiveness; prevention; health care cost; Clostridium difficile infection; antibacterial drug; FDA Adverse Event Reporting System; pharmacovigilance; disproportionality analysis; adverse reaction; Clostridioides difficile infection; efficacy; fidaxomicin; oral metronidazole; treatment failure; Clostridioides difficile; Clostridioides difficile infections; CDI; antibiotic exposure; EudraVigilance; single-center retrospective study; healthcare-associated infections; Clostridioides difficile; SARS-CoV-2; antibiotic therapy; corticosteroid therapy; intensive care unit; n/a